Cancer and the 'other' noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: A challenge to success

AIDS

Volumn 26, Issue SUPPL.1, 2012, Pages

  Hirschhorn, Lisa R ^a,b,c   Kaaya, Sylvia F ^d   Garrity, Philip S ^b   Chopyak, Elena ^a   Fawzi, Mary C S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c JSI RESEARCH AND TRAINING INSTITUTE   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

Africa; aging; cancer; HIV; neurocognitive dysfunction; noncommunicable chronic diseases; osteoporosis; renal disease

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANUS CANCER; ARTICLE; ATTENTION; BREAST CANCER; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMMUNICABLE DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXECUTIVE FUNCTION; GENERAL HEALTH QUESTIONNAIRE; HEALTH CARE SYSTEM; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; KIDNEY DISEASE; LIVER CANCER; LUNG CANCER; LUNG DISEASE; MEMORY; MENTAL HEALTH; NEOPLASM; NONCOMMUNICABLE DISEASE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; AGED; ASIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DELIVERY OF HEALTH CARE; DIABETES MELLITUS; FEMALE; HEALTH RESOURCES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LUNG DISEASES; MALE; MENTAL DISORDERS; MIDDLE AGED; NEOPLASMS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SOUTH AMERICA;

EID: 84863829515     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328355ab72     Document Type: Article

References (103)

1. Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF, Kipp AM, et al. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011; 25:1471-1479.
2. Negin J, Cumming R. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Org 2010; 88:847-853.
3. UNAIDS. UNAIDS report on the global AIDS epidemic. 2010. http://www.unaids.org/globalreport/documents/20101123-GlobalReport-full-en.pdf. (Accessed 12 March 2011)
4. Wallrauch C, Barnighausen T, Newell M-L. HIV prevalence and incidence in people 50 years and older in rural South Africa. S Afr Med J 2010; 100:812-814.
5. Hontelez JA, Lurie MN, Newell ML, Bakker R, Tanser F, Barnighausen T, et al. Aging with HIV in South Africa. AIDS 2011; 25:1665-1667.
6. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: workshop on HIV infection and aging-what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
7. Grulich A, van Leeuwan M, Falster M, Vajdic C. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. (Pubitemid 47017468)
8. Martin CP, Fain MJ, Klotz SA. The older HIV-positive adult: a critical review of the medical literature. Am J Med 2008; 121:1032-1037.
9. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Int Med 2007; 167:684-691. (Pubitemid 46598461)
10. Skiest DJ, Rubinstien E, Carley N, Gioiella L, Lyons R. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996; 101:605-611. (Pubitemid 27150038)
11. d' Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al. Cardio-and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811-1817.
12. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:29-35.
13. Gutierrez AD, Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine 2012; 41:1-10.
14. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009; 4:163-174.
15. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546. (Pubitemid 38365883)
16. Mansky KC. Aging, human immunodeficiency virus, and bone health. Clin Interv Aging 2010; 23:285-292.
17. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011; 25:561-575.
18. Section of Cancer Information. International Agency for Research on Cancer. 2008. http://www.iarc.fr/en/researchgroups/sec1/index.php. (Accessed 28 November 2011)
19. Mayosi B, Fisher A, Lalloo U, Sitas F, Tollman S, Bradshaw D. The burden of noncommunicable diseases in South Africa. Lancet 2009; 374:934-947.
20. WHO.AIDS and cancer in Africa. 2001. http://www.iarc.fr/en/publications/ pdfs-online/epi/sp153/SP153-11.pdf. (Accessed 29 November 2011)
21. UNAIDS. Chronic care of HIV and noncommunicable diseases: how to leverage the HIV experience. 2011. http://www.unaids.org/en/media/unaids/contentassets/ documents/unaidspublication/2011/20110526-JC2145-Chronic-care-of-HIV.pdf. (Accessed 29 November 2011)
22. Rabkin M, Nishtar S. Scaling up chronic care systems: leveraging HIV programs to support noncommunicable disease services. J Acquir Immune Defic Syndr 2011; 57:87-90.
23. Bedimo R, McGinnis K, Dunlap M. Incidence of non-AIDS-defining malignancies in HIV-Infected vs. noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203-208.
24. Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc 2011; 14:16.
25. Petoumenos K, Hui E, Kumarasamy N, Choi JY, Chen YM, Merati T, et al. Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc 2010; 13:1-14.
26. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
27. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among people with AIDS in the United States. Ann Intern Med 2010; 153:452-460.
28. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 2010; 5:e8621.
29. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985-990. (Pubitemid 43157675)
30. Bazoes A, Bower M, Powles T. Smoke and mirrors: HIVrelated lung cancer. Curr Opin Oncol 2008; 20:529-533.
31. Mbulaiteye SM, Bhatia K, Adebamowo C, Sasco AJ. HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. Infect Agent Cancer 2011; 6:16.
32. Goedert JJ, Schairer C, McNeel TS, Hessol NA, Rabkin CS, Engels EA. HIV/AIDS cancer match study: risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer 2006; 95:642-648. (Pubitemid 44325906)
33. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23:2337-2345.
34. Cadranel J, Garfield D, Lavolé A, Wislez M, Milleron B, Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 2006; 61:1000-10008.
35. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22:489-496. (Pubitemid 351317290)
36. Mulindi H, Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med 2011; 8:e1001032.
37. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
38. Makinson A, Tenon J-C, Eymard-Duvernay S, Pujol JL, Allavena C, Cuzin L, et al. Human immunodeficiency virus infection and nonsmall cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6:1022-1029.
39. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80:1258-1270.
40. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354:997-999. (Pubitemid 43357803)
41. Arogundade FA, Barsoum RS. CKD prevention in sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis 2008; 51:515-523. (Pubitemid 351284498)
42. Winkler CA, Nelson G, Oleksyk TK, Nava MB, Kopp JB. Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. Semin Nephrol 2010; 30:111-125.
43. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008; 22:1821-1827.
44. Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 2008; 23:741-746. (Pubitemid 351767653)
45. Menezes AM, Torelly J, Real L, Bay M, Poeta J, Sprinz E. Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One 2011; 6:e26042.
46. Cailhol J, Nkurunziza B, Izzedine H, Nindagiye E, Munyana L, Baramperanye E, et al. Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a crosssectional study. BMC Nephrol 2011; 12:40.
47. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat 2011; 2011:562790.
48. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
49. Kaufman L, Collins SE, Klotman PE. The pathogenesis of HIV-associated nephropathy. Adv Chronic Kidney Dis 2010; 17:36-43.
50. Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006; 1:655-667.
51. Gupta SK, Ong'or WO, Shen C, Musick B, Goldman M, Wools-Kaloustian K. Reduced renal function is associated with progression to AIDS but not with overall mortality in HIVinfected Kenyan adults not initially requiring combination antiretroviral therapy. J Int AIDS Soc 2011; 14:31.
52. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, D'Agati VD, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009; 75:428-434.
53. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010. http://www.who.int/hiv/pub/ arv/adult2010/en/. (Accessed 20 November 2011)
54. Stohr W, Reid A, Walker AS, Munderi F, Mambule I, Kityo C, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther 2011; 16:1011-1020.
55. Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, et al. Renal function declines more in tenofovirthan abacavir-based antiretroviral therapy in low-body weight treatment-na?̈ve patients with HIV infection. PLoS One 2012; 7:e29977.
56. Raviola G, Becker AE, Farmer P. A global scope for global health: including mental health. Lancet 2011; 6736: 10-11.
57. Belkin G, Unü tzer J, Kessler R, Verdeli H, Raviola G, Sachs K, et al. Scaling up for the 'Bottom Billion': '5T5' implementation of community mental healthcare in low-income regions. Psychiatr Serv 2011; 62:1-9.
58. Sayers J. The World Health Report 2001: mental health: new understanding, new hope. Bull World Health Organ 2001; 79:1085. http://www.who.int/whr/2001/ en/. (Accessed 5 March 2012)
59. Lund C, Breen A, Flisher AJ, Kakuma R, Corrigall J, Joska JA, et al. Poverty and common mental disorders in low and middle income countries: a systematic review. Soc Sci Med 2010; 71:517-528.
60. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. Lancet 2007; 370:859-877. (Pubitemid 47371145)
61. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 2006; 66:769-789. (Pubitemid 43765224)
62. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158:725-730. (Pubitemid 32429839)
63. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423. (Pubitemid 32955198)
64. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav 2011. [Epub ahead of print]
65. Marwick KFM, Kaaya SF. Prevalence of depression and anxiety disorders in HIV-positive outpatients in rural Tanzania. AIDS Care 2010; 22:415-419.
66. Wright EJ, Nunn M, Joseph J, Robertson K, Lal L, Brew BJ. Neuro-AIDS in the Asia Pacific region. J Neurovirol 2008; 14:465-473.
67. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J Acquir Immune Defic Syndr 2007; 44:470-477. (Pubitemid 46555384)
68. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008; 70:539-545.
69. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45:394-402. (Pubitemid 39166911)
70. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002; 159:1752-1759.
71. Dowshen N, Binns HJ, Garofalo R. Experiences of HIV-related stigma among young men who have sex with men. AIDS Patient Care STDs 2009; 23:371-376.
72. Wu DY, Munoz M, Espiritu B, Zeladita J, Sanchez E, Callacna M, et al. Burden of depression among impoverished HIVpositive women in Peru. J Acquir Immune Defic Syndr 2008; 48:500-504.
73. Mathers BM, Degenhardt L, Adam P, Toskin I, Nashkhoev M, Lyerla R, et al. Estimating the level of HIV prevention, coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? J Acquir Immune Defic Syndr 2009; 52:132-142.
74. Klein RS. Trends related to aging and co-occurring disorders in HIV-infected drug users. Subst Use Misuse 2011; 46:233-244.
75. Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks HS. Aging and HIV infection. J Urban Health 2006; 83:31-42. (Pubitemid 44337041)
76. Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 2004; 18:S11-S18. (Pubitemid 38365901)
77. Malaspina L, Woods SP, Moore DJ, Depp C, Letendre SL, Jeste D, et al. Successful cognitive aging in persons living with HIV infection. J Neurovirol 2011; 17:110-119.
78. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004; 63:822-827. (Pubitemid 39297641)
79. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
80. Robertson K, Liner J, Hakim J, Sankalé JL, Grant I, Letendre S, et al. Neuro-AIDS in Africa. J Neurovirol 2010; 16:189-202.
81. Sacktor N, Nakasujja N, Robertson K, Clifford DB. HIVassociated cognitive impairment in sub-Saharan Africa: the potential effect of clade diversity. Nat Clin Pract Neurol 2007; 3:436-443. (Pubitemid 47202500)
82. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16:101-114.
83. Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18:S27-S34. (Pubitemid 38365903)
84. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 2011; 24:275-283.
85. Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry 2010; 67:1282-1290.
86. Fulk LJ, Kane BE, Phillips KD, Bopp CM, Hand GA. Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res 2004; 57:339-351. (Pubitemid 39424246)
87. Gourevitch MN. Interactions between HIV-related medications and methadone: an overview. Updated March 2001. Mt Sinai J Med N Y 2001; 68:227-228.
88. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
89. Atoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36:1598-1613.
90. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.AmJ Respir Crit Care Med 2001; 163:1256-1276.
91. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodrigues-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183:388-395.
92. Oursler KK, Goulet JL, Crystal S, Justice AC, Crothers K, Butt AA, et al. Association of age and comorbidity with physical function in HIV-infected and uninfected patients: results from the Veterans Aging Cohort Study. AIDS Patient Care STDS 2011; 25:13-20.
93. Diaz P, King M, Pacht E, Wewers MD, Gadek JE, Nagaraja HN, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132:369-372. (Pubitemid 30127775)
94. WHO. Framework Convention on Tobacco Control. 2005. http://apps.who.int/ fctc/reporting/database/. (Accessed 3 March 2012)
95. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
96. Kruger MC, Kruger IM, Wentzel-Viljoen E, Kruger A. Urbanization of black South African women may increase risk of low bone mass due to low vitamin D status, low calcium intake, and high bone turnover. Nutr Res 2011; 31:748-758.
97. Hasse B, Ledergerber B, Furrer H, Battegay M, Hischel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
98. Brown TT, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic study. AIDS 2006; 20:2165-2174. (Pubitemid 44684707)
99. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIVinfected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
100. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
101. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-946.
102. Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovirDFvs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
103. Holmes MD, Dalal S, Volmink J, Adebamowo CA, Njelekela M, Fawzi WW, et al. Noncommunicable diseases in sub-Saharan Africa: the case for cohort studies. PLoS Med 2010; 7:e1000244.